Gyre Therapeutics, Inc. (GYRE) stock
GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)
Close on Nov 18, 2026Market cap $483.95MP/E –Yield –
Gyre Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Gyre Therapeutics's enterprise value was $428.92M on Nov 11, 2026, against $679.85M a year earlier. Over the last 5 years it ranged from $109.17M to $1.39B, with a median of $650.41M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $428.92M | -30.5% |
| 2025 | Dec 31, 2025 | $617.13M | -41.1% |
| 2024 | Dec 31, 2024 | $1.05B | +7.7% |
| 2023 | Dec 29, 2023 | $973.43M | +328.3% |
| 2022 | Dec 30, 2022 | $227.26M | -4.2% |
| 2021 | Dec 31, 2021 | $237.14M | -88.1% |
| 2020 | Dec 31, 2020 | $1.99B | +73.6% |
| 2019 | Dec 31, 2019 | $1.14B | -10.9% |
| 2018 | Dec 31, 2018 | $1.28B | +50.3% |
| 2017 | Dec 29, 2017 | $854.45M | +782.2% |
| 2016 | Dec 30, 2016 | $96.86M | -80.6% |
| 2015 | Dec 31, 2015 | $499.02M | +982.4% |
| 2014 | Dec 31, 2014 | $46.10M | -28.0% |
| 2013 | Dec 31, 2013 | $64.01M | +141.7% |
| 2012 | Dec 31, 2012 | $26.49M | +961.4% |
| 2011 | Dec 30, 2011 | $2.50M | -99.6% |
| 2010 | Dec 31, 2010 | $691.45M | – |
See a number that looks wrong?